Lerkanidypina – potwierdzamy fakty i obalamy mity Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2024
Słowa kluczowe:
lerkanidypina, antagoniści kanałów wapniowych, obrzęki, nadciśnienie tętnicze
##plugins.themes.bootstrap3.article.main##
Abstrakt
Lerkanidypina jest przedstawicielem jednej z podstawowych grup leków hipotensyjnych – dihydropirydynowych antagonistów kanałów wapniowych III generacji. Działając głównie na napięciowozależne kanały typu L, hamuje napływ jonów wapnia do komórek mięśni gładkich. Cechuje ją wysoce selektywne działanie na mięśniówkę naczyń krwionośnych, dzięki czemu nie ma ona działania inotropowego ujemnego. Lerkanidypina dzięki swoim właściwościom lipofilnym z łatwością przenika do warstwy hydrofobowej błony komórkowej i jest w niej magazynowana. Zapewnia jej to powolny początek oraz długi czas działania mimo krótkiego okresu półtrwania w surowicy. Dzięki temu nie powoduje ona odruchowej tachykardii ani pobudzenia układu współczulnego. Co więcej ponad 2-krotnie redukuje ryzyko wystąpienia obrzęków obwodowych w stosunku do nielipofilnych antagonistów kanałów wapniowych (RR = 0,44; 95% CI: 0,31–0,62; p <0,001), co istotnie poprawia compliance i persistance. Poza działaniem hipotensyjnym opisano korzystne działanie lerkanidypiny na wiele innych układów, w tym unikalne działanie nefroprotekcyjne. Redukcja białkomoczu jest możliwa dzięki blokowaniu kanałów wapniowych typów L i T, co powoduje rozszerzenie tętniczek doprowadzających i odprowadzających w kłębuszku nerkowym. Lerkanidypina jest bezpiecznym i skutecznym lekiem niezależnie od płci i wieku pacjentów.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kochanowska, A., & Wełnicki, M. (2024). Lerkanidypina – potwierdzamy fakty i obalamy mity. Medycyna Faktów , 17(4(65), 503-510. https://doi.org/10.24292/01.MF.0424.11
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther. 2009; 31(8): 1652-63.
2. Cao TS, Huynh VM, Tran VH. Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. Curr Med Res Opin. 2015; 31(1): 163-70.
3. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens. 1998; 16(12 Pt 1): 1831-8.
4. Burnier M, Gasser UE. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother. 2007; 8(14): 2215-23.
5. Mazzaglia G, Ambrosioni E, Alacqua M et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009; 120(16): 1598-605.
6. Treciokiene I, Bratcikoviene N, Gulbinovic J et al. Non-persistence to antihypertensive drug therapy in Lithuania. Eur J Clin Pharmacol. 2022; 78(10): 1687-96.
7. Kronish IM, Woodward M, Sergie Z et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011; 123(15): 1611-21.
8. Veronesi M, Cicero AF, Prandin MG et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007; 3(6): 999-1005.
9. Makani H, Bangalore S, Romero J et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate – a meta-analysis of randomized trials. J Hypertens. 2011; 29(7): 1270-80.
10. Liang H, Zhang X, Ma Z et al. Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension. Pharmgenomics Pers Med. 2021; 14: 189-197.
11. Liang L, Kung JY, Mitchelmore B et al. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2022; 24(5): 536-54.
12. Makani H, Bangalore S, Romero J et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011; 124(2): 128-35.
13. Borghi C, Prandin MG, Dormi A et al.; Study Group of the Regional Unit of the Italian Society of Hypertension. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl. 2003; 1: 14-21.
14. Barrios V, Escobar C, de la Figuera M et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract. 2008; 62(5): 723-8.
15. Cheng KH, Cheng KC, Cheng KY et al. Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. Curr Med Res Opin. 2017; 33(6): 1111-7.
16. Cerbai E, Mugelli A. Lercanidipine and T-type calcium current. Eur Rev Med Pharmacol Sci. 2018; 22(12): 4025-31.
17. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension. 2000; 35(3): 775-9.
18. Sabbatini M, Leonardi A, Testa R et al. Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2002; 39(1): 39-48.
19. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004; 17(5): 259-66.
20. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-86.
21. Viviani GL. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol. 2002; 40(1): 133-9.
22. Barrios V, Calderon A, Navarro A et al. Lercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG study. J Hypertens. 2004; 22(Suppl. 2): S258-9.
23. Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs. 1999; 8(7): 1043-62.
24. Angelico P, Guarneri L, Leonardi A et al. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol. 1999; 51(6): 709-14.
25. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3): 290-300.
26. McEvoy JW, McCarthy CP, Bruno RM et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45(38): 3912-4018.
27. Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41(12): 1874-2071.
28. Mancia G, Coca A, Chazova I et al.; FELT investigators. Effects on office and home blood pressure of the lercanidipine enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J Hypertens. 2014; 32(8): 1700-7.
29. Poncelet P, Ribstein J, Goullard L et al. Efficacité et la tolérance de la lercanidipine ne sont pas liées à l’âge des patients hypertendus: étude AGATE [Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study]. Ann Cardiol Angeiol (Paris). 2004; 53(3): 123-30.
30. Leonetti G, Magnani B, Pessina AC et al.; COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002; 15(11): 932-40.
31. Lund-Johansen P, Stranden E, Helberg S et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens. 2003; 21(5): 1003-10.
32. Prejbisz A, Dobrowolski P, Kosiński P et al. Management of hypertension in pregnancy: prevention, diagnosis, treatment and long‑term prognosis. Kardiol Pol. 2019; 77(7-8): 757-806.
33. Prejbisz A, Dobrowolski P, Doroszko A et al. Guidelines for the management of hypertension in Poland 2024 – the position of the Polish Society of Hypertension/Polish Cardiac Society Experts. Arterial Hypertension, 2024. 28(0): 91-146.
34. De Ciuceis C, Salvetti M, Rossini C et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens. 2014; 32(3): 565-74.
35. Rachmani R, Levi Z, Zadok BS et al. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther. 2002; 72(3): 302-7.
36. Farah R, Khamisy-Farah R, Shurtz-Swirski R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol. 2013; 32(1): 85-93.
37. Martinez ML, Lopes LF, Coelho EB et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006; 47(1): 117-22.
2. Cao TS, Huynh VM, Tran VH. Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. Curr Med Res Opin. 2015; 31(1): 163-70.
3. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens. 1998; 16(12 Pt 1): 1831-8.
4. Burnier M, Gasser UE. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother. 2007; 8(14): 2215-23.
5. Mazzaglia G, Ambrosioni E, Alacqua M et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009; 120(16): 1598-605.
6. Treciokiene I, Bratcikoviene N, Gulbinovic J et al. Non-persistence to antihypertensive drug therapy in Lithuania. Eur J Clin Pharmacol. 2022; 78(10): 1687-96.
7. Kronish IM, Woodward M, Sergie Z et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011; 123(15): 1611-21.
8. Veronesi M, Cicero AF, Prandin MG et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007; 3(6): 999-1005.
9. Makani H, Bangalore S, Romero J et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate – a meta-analysis of randomized trials. J Hypertens. 2011; 29(7): 1270-80.
10. Liang H, Zhang X, Ma Z et al. Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension. Pharmgenomics Pers Med. 2021; 14: 189-197.
11. Liang L, Kung JY, Mitchelmore B et al. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2022; 24(5): 536-54.
12. Makani H, Bangalore S, Romero J et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011; 124(2): 128-35.
13. Borghi C, Prandin MG, Dormi A et al.; Study Group of the Regional Unit of the Italian Society of Hypertension. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl. 2003; 1: 14-21.
14. Barrios V, Escobar C, de la Figuera M et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract. 2008; 62(5): 723-8.
15. Cheng KH, Cheng KC, Cheng KY et al. Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. Curr Med Res Opin. 2017; 33(6): 1111-7.
16. Cerbai E, Mugelli A. Lercanidipine and T-type calcium current. Eur Rev Med Pharmacol Sci. 2018; 22(12): 4025-31.
17. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension. 2000; 35(3): 775-9.
18. Sabbatini M, Leonardi A, Testa R et al. Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2002; 39(1): 39-48.
19. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004; 17(5): 259-66.
20. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-86.
21. Viviani GL. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol. 2002; 40(1): 133-9.
22. Barrios V, Calderon A, Navarro A et al. Lercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG study. J Hypertens. 2004; 22(Suppl. 2): S258-9.
23. Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs. 1999; 8(7): 1043-62.
24. Angelico P, Guarneri L, Leonardi A et al. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol. 1999; 51(6): 709-14.
25. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3): 290-300.
26. McEvoy JW, McCarthy CP, Bruno RM et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45(38): 3912-4018.
27. Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41(12): 1874-2071.
28. Mancia G, Coca A, Chazova I et al.; FELT investigators. Effects on office and home blood pressure of the lercanidipine enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J Hypertens. 2014; 32(8): 1700-7.
29. Poncelet P, Ribstein J, Goullard L et al. Efficacité et la tolérance de la lercanidipine ne sont pas liées à l’âge des patients hypertendus: étude AGATE [Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study]. Ann Cardiol Angeiol (Paris). 2004; 53(3): 123-30.
30. Leonetti G, Magnani B, Pessina AC et al.; COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002; 15(11): 932-40.
31. Lund-Johansen P, Stranden E, Helberg S et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens. 2003; 21(5): 1003-10.
32. Prejbisz A, Dobrowolski P, Kosiński P et al. Management of hypertension in pregnancy: prevention, diagnosis, treatment and long‑term prognosis. Kardiol Pol. 2019; 77(7-8): 757-806.
33. Prejbisz A, Dobrowolski P, Doroszko A et al. Guidelines for the management of hypertension in Poland 2024 – the position of the Polish Society of Hypertension/Polish Cardiac Society Experts. Arterial Hypertension, 2024. 28(0): 91-146.
34. De Ciuceis C, Salvetti M, Rossini C et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens. 2014; 32(3): 565-74.
35. Rachmani R, Levi Z, Zadok BS et al. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther. 2002; 72(3): 302-7.
36. Farah R, Khamisy-Farah R, Shurtz-Swirski R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol. 2013; 32(1): 85-93.
37. Martinez ML, Lopes LF, Coelho EB et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006; 47(1): 117-22.